Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,141 shares of the biopharmaceutical company’s stock after selling 2,103 shares during the quarter. Fifth Third Bancorp’s holdings in Regeneron Pharmaceuticals were worth $20,580,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth about $5,682,636,000. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. Bank of America Corp DE raised its holdings in Regeneron Pharmaceuticals by 2.8% in the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock valued at $919,120,000 after acquiring an additional 32,158 shares in the last quarter. Amundi raised its holdings in Regeneron Pharmaceuticals by 27.5% in the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after acquiring an additional 217,892 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $473,872,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $542,700. This trade represents a 39.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine A. Poon sold 7,830 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the transaction, the director directly owned 5,219 shares in the company, valued at $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 27,028 shares of company stock worth $25,025,950 over the last 90 days. Company insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on REGN. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. increased their target price on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $898.97.

Read Our Latest Research Report on REGN

Regeneron Pharmaceuticals Stock Up 0.4%

REGN opened at $955.47 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $591.52 and a one year high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. The stock has a market capitalization of $98.84 billion, a P/E ratio of 21.10, a price-to-earnings-growth ratio of 1.26 and a beta of 0.10. The business’s 50-day simple moving average is $816.17 and its 200-day simple moving average is $747.36.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue was up 36.3% on a year-over-year basis. During the same period in the prior year, the firm earned $11.83 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.